These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 21249726)

  • 1. Influence of intravenous administration of growth hormone releasing peptide-2 (GHRP-2) on detection of growth hormone doping: growth hormone isoform profiles in Japanese male subjects.
    Okano M; Nishitani Y; Sato M; Ikekita A; Kageyama S
    Drug Test Anal; 2010; 2(11-12):548-56. PubMed ID: 21249726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of GH isoform differential immunoassay for detecting rhGH doping on application of various growth factors.
    Okano M; Nishitani Y; Sato M; Kageyama S
    Drug Test Anal; 2012 Sep; 4(9):692-700. PubMed ID: 22733714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abuse of recombinant human growth hormone: studies in two different dog models.
    Rigamonti AE; Scanniffio D; Bonomo SM; Cella SG; Sartorio A; Müller EE
    Neuroendocrinology; 2004; 79(5):237-46. PubMed ID: 15218318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tracking growth hormone abuse in sport: a comparison of distinct isoform-based assays.
    Bosch J; Ueki M; Such-Sanmartín G; Segura J; Gutiérrez-Gallego R
    Anal Chim Acta; 2012 Jul; 733():56-63. PubMed ID: 22704376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined evaluation of resting IGF1, N-terminal propeptide of type III procollagen and C-terminal cross-linked telopeptide of type I collagen levels might be useful for detecting inappropriate GH administration in female athletes.
    Di Luigi L; Rigamonti AE; Agosti F; Mencarelli M; Sgrò P; Marazzi N; Cella SG; Müller EE; Sartorio A
    Eur J Endocrinol; 2009 May; 160(5):753-8. PubMed ID: 19258430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports.
    Bidlingmaier M; Suhr J; Ernst A; Wu Z; Keller A; Strasburger CJ; Bergmann A
    Clin Chem; 2009 Mar; 55(3):445-53. PubMed ID: 19168559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinally monitoring of P-III-NP, IGF-I, and GH-2000 score increases the probability of detecting two weeks' administration of low-dose recombinant growth hormone compared to GH-2000 decision limit and GH isoform test and micro RNA markers.
    Lehtihet M; Bhuiyan H; Dalby A; Ericsson M; Ekström L
    Drug Test Anal; 2019 Mar; 11(3):411-421. PubMed ID: 30223291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarker detection of rhGH doping: an excretion study.
    Jing J; Zhou X; He C; Zhang L; Yang S; Xu Y; Xie M; Yan Y; Su H; Wu M
    Drug Test Anal; 2012 Oct; 4(10):739-44. PubMed ID: 23074170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. hGH isoform differential immunoassays applied to blood samples from athletes: decision limits for anti-doping testing.
    Hanley JA; Saarela O; Stephens DA; Thalabard JC
    Growth Horm IGF Res; 2014 Oct; 24(5):205-15. PubMed ID: 24973245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of new growth promoting black market products.
    Krug O; Thomas A; Malerød-Fjeld H; Dehnes Y; Laussmann T; Feldmann I; Sickmann A; Thevis M
    Growth Horm IGF Res; 2018 Aug; 41():1-6. PubMed ID: 29864719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a microplate duplex immunoassay to simplify detection of growth hormone doping: Proof of concept.
    Marchand A; Roy D; Monsheimer SA; Lewis J; Ericsson M
    Drug Test Anal; 2022 Apr; 14(4):724-732. PubMed ID: 34761559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone in sports: detecting the doped or duped.
    Ho KK; Nelson AE
    Horm Res Paediatr; 2011; 76 Suppl 1():84-90. PubMed ID: 21778756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detecting growth hormone abuse in athletes.
    Bidlingmaier M; Manolopoulou J
    Endocrinol Metab Clin North Am; 2010 Mar; 39(1):25-32, vii. PubMed ID: 20122447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.
    Bowers CY; Granda R; Mohan S; Kuipers J; Baylink D; Veldhuis JD
    J Clin Endocrinol Metab; 2004 May; 89(5):2290-300. PubMed ID: 15126555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.
    Semenistaya E; Zvereva I; Thomas A; Thevis M; Krotov G; Rodchenkov G
    Drug Test Anal; 2015 Oct; 7(10):919-25. PubMed ID: 25869809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral estradiol administration modulates continuous intravenous growth hormone (GH)-releasing peptide-2-driven GH secretion in postmenopausal women.
    Shah N; Evans WS; Bowers CY; Veldhuis JD
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2649-59. PubMed ID: 10946861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion.
    Muller AF; Janssen JA; Lamberts SW; Bidlingmaier M; Strasburger CJ; Hofland L; van der Lely AJ
    Clin Endocrinol (Oxf); 2001 Oct; 55(4):461-7. PubMed ID: 11678828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry.
    Thomas A; Höppner S; Geyer H; Schänzer W; Petrou M; Kwiatkowska D; Pokrywka A; Thevis M
    Anal Bioanal Chem; 2011 Aug; 401(2):507-16. PubMed ID: 21298258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine and metabolic effects of growth hormone (GH) compared with GH-releasing peptide, thyrotropin-releasing hormone, and insulin infusion in a rabbit model of prolonged critical illness.
    Weekers F; Michalaki M; Coopmans W; Van Herck E; Veldhuis JD; Darras VM; Van den Berghe G
    Endocrinology; 2004 Jan; 145(1):205-13. PubMed ID: 14551231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex.
    Guha N; Erotokritou-Mulligan I; Bartlett C; Nevitt SP; Francis M; Bassett EE; Cowan DA; Sönksen PH; Holt RI
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2259-68. PubMed ID: 24606087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.